Stock CLDX CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Real-time Estimate Cboe BZX
Other stock markets
 10:10:34 2024-06-10 am EDT 		5-day change 1st Jan Change
34.18 USD -3.10% Intraday chart for Celldex Therapeutics, Inc. +3.03% -13.05%
Jun. 05 Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing MT
Jun. 05 Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing
MT
Celldex Therapeutics to Present at Jefferies Healthcare Conference
AQ
Celldex Therapeutics Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $1,319,156, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $1,298,384, According to a Recent SEC Filing
MT
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
AQ
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024
CI
Certain Common Stock of Celldex Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Certain Stock Options of Celldex Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study
MT
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
AQ
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
CI
Celldex: Q1 Earnings Snapshot
AQ
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000
MT
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
MT
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise
MT
Celldex Therapeutics : Corporate Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. News Celldex Therapeutics, Inc.